Ankylosing spondylitis
News from the FDA/CDC
FDA approves ixekizumab for nonradiographic axSpA
This is the first IL-17A antagonist to receive FDA approval for this indication.
Conference Coverage
Nonpharmacologic ankylosing spondylitis recommendations not followed
Disease activity was measured in only 17% of office visits.
Conference Coverage
Inflammatory back pain likely underrecognized in primary care
They “did not seem to be screening for it.”
Conference Coverage
TNF inhibitors may dampen COVID-19 severity
New findings from the COVID-19 Global Rheumatology Alliance Registry.
Commentary
Advice on treating rheumatic diseases from a COVID-19 epicenter
Hospital for Special Surgery rheumatologists discuss their approach to caring for patients with rheumatic diseases within their practice during...
Guidelines
ACR gives guidance on rheumatic disease management during pandemic
When COVID-19 is suspected, rheumatic disease patients may continue their hydroxychloroquine but other rheumatic disease treatments may need to be...
From the Journals
Case series suggests biologics, JAK inhibitors safe during pandemic
Investigators saw no increase in hospitalizations versus the general population in New York City.
From the Journals
Sacroiliac bone marrow edema on MRI may be common postpartum
When suspecting axial spondyloarthritis, clinicians may need to wait at least 6 months after delivery to perform an MRI of the sacroiliac joints...
Conference Coverage
Differentiating hypersensitivity reactions to monoclonal antibodies
MAUI, HAWAII – Who to send to the allergist for desensitization.
From the Journals
Financial incentives affect the adoption of biosimilars
Adoption of infliximab biosimilars proceeded more slowly at an academic medical center than at a neighboring VAMC, where financial incentives to...
Feature
‘We’re in great distress here,’ infusion center CMO says
Thrivewell is also deploying a mobile infusion unit to recovered COVID-19 patients who require an infusion for their autoimmune disease.